{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:27:09Z","timestamp":1784708829899,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report a case of intraocular inflammation following adjuvanted recombinant Varicella-Zoster subunit vaccine (RZV) in a patient with previously resolved VZV-related acute retinal necrosis (ARN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single case report. Multimodal imaging, including true-color fundus photography, spectral-domain (SD-OCT) and dye-based angiography, was used to evaluate the retinal alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 73-year-old male, with past history of VZV-related acute retinal necrosis (ARN) developed unilateral cystoid macular edema and diffuse blood-retinal barrier (BRB) breakdown in the affected eye after receiving the second dose of RZV vaccine. A complete resolution of this complication was observed after a short course of systemic corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our case suggests a possible pathogen-specific intraocular inflammatory reaction, resembling immune reconstitution uveitis (IRU), following RZV administration in a patient with previously resolved VZV-related ARN. While RZV remains safe, intraocular inflammation should be considered as a possible side effect in patients with previously resolved VZV uveitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-025-00508-3","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T03:33:42Z","timestamp":1754105622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unilateral uveitis following adjuvanted Varicella-Zoster subunit vaccine in a patient with previously resolved Varicella Zoster acute retinal necrosis"],"prefix":"10.1186","volume":"15","author":[{"given":"A.","family":"Trinco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zicarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"508_CR1","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification Criteria for Acute Retinal Necrosis Syndrome. Am J Ophthalmol. 228:237-244."},{"issue":"10","key":"508_CR2","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.ophtha.2009.03.029","volume":"116","author":"J Hillenkamp","year":"2009","unstructured":"Hillenkamp J, N\u00f6lle B, Bruns C, Rautenberg P, Fickenscher H, Roider J (2009) Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 116(10):1971\u20135. e2","journal-title":"Ophthalmology."},{"issue":"3","key":"508_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ophtha.2016.11.007","volume":"124","author":"SD Schoenberger","year":"2017","unstructured":"Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya P, Yeh S, Bakri SJ, Ehlers JP (2017) Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. Ophthalmology. 124(3):382\u201392","journal-title":"Ophthalmology."},{"issue":"2","key":"508_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICB.0000000000000761","volume":"15","author":"M Menghini","year":"2021","unstructured":"Menghini M, Raja V, Raiter J, Balaratnasingam C, Constable IJ (2021) Acute retinal necrosis associated with herpes zoster vaccination. Retin Cases Brief Rep. 15(2):166\u20138","journal-title":"Retin Cases Brief Rep."},{"issue":"12","key":"508_CR5","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/cid\/cix683","volume":"65","author":"G Heath","year":"2017","unstructured":"Heath G, Depledge DP, Brown JR, Hale AD, Tutil H, Williams R, Breuer J (2017) Acute Retinal Necrosis Caused by the Zoster Vaccine Virus. Clin Infect Dis. 65(12):2122\u20135","journal-title":"Clin Infect Dis."},{"issue":"1","key":"508_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/ICB.0000000000000729","volume":"15","author":"A Ali","year":"2021","unstructured":"Ali A, Kirschenbaum MD, Sharma S, Wandel TL (2021) Acute retinal necrosis and contralateral cutaneous eruption after the shingles vaccine. Retin Cases Brief Rep. 15(1):43\u20134","journal-title":"Retin Cases Brief Rep."},{"issue":"4","key":"508_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 3(4):109\u201320","journal-title":"Ther Adv Vaccines."},{"issue":"6","key":"508_CR8","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","volume":"17","author":"D Van Oorschot","year":"2021","unstructured":"Van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B (2021) A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 17(6):1714\u201332","journal-title":"Hum Vaccin Immunother."},{"issue":"8","key":"508_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/21645515.2017.1317410","volume":"13","author":"T Bharucha","year":"2017","unstructured":"Bharucha T, Ming D, Breuer J (2017) A critical appraisal of \u201cShingrix\u201d, a novel herpes zoster subunit vaccine (HZ\/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 13(8):1789\u201397","journal-title":"Hum Vaccin Immunother."},{"key":"508_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","volume":"59","author":"TC Heineman","year":"2019","unstructured":"Heineman TC, Cunningham A, Levin M (2019) Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 59:42\u20138","journal-title":"Curr Opin Immunol."},{"key":"508_CR11","doi-asserted-by":"crossref","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, D\u00edez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barber\u00e0 J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group (2016). Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 375(11):1019-32.","DOI":"10.1056\/NEJMoa1603800"},{"issue":"2","key":"508_CR12","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S2468-2667(17)30234-7","volume":"3","author":"G Amirthalingam","year":"2018","unstructured":"Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, Ramsay M (2018) Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 3(2):e82-90","journal-title":"Lancet Public Health."},{"issue":"4","key":"508_CR13","doi-asserted-by":"publisher","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","volume":"10","author":"SM Langan","year":"2013","unstructured":"Langan SM, Smeeth L, Margolis DJ, Thomas SL (2013) Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 10(4):e1001420","journal-title":"PLoS Med."},{"issue":"12","key":"508_CR14","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"HF Tseng","year":"2016","unstructured":"Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ (2016) Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged \u226560 Years. J Infect Dis. 213(12):1872\u20135","journal-title":"J Infect Dis."},{"issue":"6","key":"508_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/cid\/ciab121","volume":"73","author":"Y Sun","year":"2021","unstructured":"Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR (2021) Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin Infect Dis. 73(6):949\u201356","journal-title":"Clin Infect Dis."},{"issue":"6","key":"508_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/cid\/ciab125","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, MaCurdy TE, Kelman J, Dooling K (2021) Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin Infect Dis. 73(6):941\u20138","journal-title":"Clin Infect Dis."},{"issue":"4","key":"508_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","volume":"68","author":"EM Hesse","year":"2019","unstructured":"Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV (2019) Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep. 68(4):91\u20134","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"508_CR18","unstructured":"Food and Drug Administration. briefing document FDA: Shingrix (zoster vaccine recombinant, adjuvanted). Presented at the Vaccines and Related Biological Products Advisory Committee meeting, Silver Spring, MD; September 13, 2017. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM575190.pdf"},{"key":"#cr-split#-508_CR19.1","unstructured":"Summary of product characteristics: Shingrix: European Medicines Agency. 2020 [ updated 2020 Sep 28"},{"key":"#cr-split#-508_CR19.2","unstructured":"cited 2020 Oct 2]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf"},{"issue":"4","key":"508_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bjophthalmol-2017-310210","volume":"102","author":"A Invernizzi","year":"2018","unstructured":"Invernizzi A, Agarwal AK, Ravera V, Mapelli C, Riva A, Staurenghi G, McCluskey PJ, Viola F (2018) Comparing optical coherence tomography findings in different aetiologies of infectious necrotising retinitis. Br J Ophthalmol. 102(4):433\u20137","journal-title":"Br J Ophthalmol."},{"issue":"1","key":"508_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/IAE.0000000000001503","volume":"38","author":"A Invernizzi","year":"2018","unstructured":"Invernizzi A, Agarwal A, Ravera V, Oldani M, Staurenghi G, Viola F (2018) Optical coherence tomography findings in cytomegalovirus retinitis: A Longitudinal Study. Retina. 38(1):108\u201317","journal-title":"Retina."},{"issue":"2","key":"508_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.survophthal.2021.04.001","volume":"67","author":"JY Cheng","year":"2022","unstructured":"Cheng JY, Margo CE (2022) Ocular adverse events following vaccination: overview and update. Surv Ophthalmol. 67(2):293\u2013306","journal-title":"Surv Ophthalmol."},{"issue":"10","key":"508_CR23","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/vaccines11101626","volume":"11","author":"Y Zou","year":"2023","unstructured":"Zou Y, Kamoi K, Zong Y, Zhang J, Yang M, Ohno-Matsui K (2023) Ocular Inflammation Post-Vaccination. Vaccines (Basel). 11(10):1626","journal-title":"Vaccines (Basel)."},{"issue":"11","key":"508_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/vaccines10111879","volume":"10","author":"P Ichhpujani","year":"2022","unstructured":"Ichhpujani P, Parmar UPS, Duggal S, Kumar S (2022) COVID-19 Vaccine-Associated Ocular Adverse Effects: An Overview. Vaccines (Basel). 10(11):1879","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"508_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000522272","volume":"13","author":"TJ Lu","year":"2022","unstructured":"Lu TJ, Ta CN (2022) Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine. Case Rep Ophthalmol. 13(1):104\u20138","journal-title":"Case Rep Ophthalmol."},{"issue":"20","key":"508_CR26","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.ajoc.2020.100962","volume":"8","author":"RI Chen","year":"2020","unstructured":"Chen RI, Deaner JD, Srivastava SK, Lowder CY (2020) Acute retinal necrosis following recombinant subunit varicella-zoster virus vaccine. Am J Ophthalmol Case Rep. 8(20):100962","journal-title":"Am J Ophthalmol Case Rep."},{"issue":"2","key":"508_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00003226-199303000-00007","volume":"12","author":"H Wenkel","year":"1993","unstructured":"Wenkel H, Rummelt C, Rummelt V, Jahn G, Fleckenstein B, Naumann GO (1993) Detection of varicella zoster virus DNA and viral antigen in human cornea after herpes zoster ophthalmicus. Cornea. 12(2):131\u20137","journal-title":"Cornea."},{"issue":"9","key":"508_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/jmv.24807","volume":"89","author":"SK Mehta","year":"2017","unstructured":"Mehta SK, Nelman-Gonzalez M, Tyring SK, Tong Y, Beitman A, Crucian BE, Renner AN, Pierson DL (2017) Localization of VZV in saliva of zoster patients. J Med Virol. 89(9):1686\u20139","journal-title":"J Med Virol."},{"issue":"7\u20138","key":"508_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/09273948.2021.1922926","volume":"30","author":"SL Hojjatie","year":"2022","unstructured":"Hojjatie SL, Shantha JG, O\u2019Keefe GD, Kraft CS, Voloschin A, Grossniklaus H, Yeh S (2022) Cytopathology of Vitreous Specimens in Acute Retinal Necrosis. Ocul Immunol Inflamm. 30(7\u20138):1609\u201316","journal-title":"Ocul Immunol Inflamm."},{"issue":"2","key":"508_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1086\/515638","volume":"178","author":"H Kimura","year":"1998","unstructured":"Kimura H, Wang Y, Pesnicak L, Cohen JI, Hooks JJ, Straus SE, Williams RK (1998) Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. J Infect Dis. 178(2):310\u20137","journal-title":"J Infect Dis."},{"issue":"11","key":"508_CR31","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.ophtha.2018.08.030","volume":"125","author":"A Lehmann","year":"2018","unstructured":"Lehmann A, Matoba A (2018) Reactivation of Herpes Zoster Stromal Keratitis After HZ\/su Adjuvanted Herpes Zoster Subunit Vaccine. Ophthalmology. 125(11):1682","journal-title":"Ophthalmology."},{"issue":"6","key":"508_CR32","first-page":"3278","volume":"11","author":"M Heydari-Kamjani","year":"2019","unstructured":"Heydari-Kamjani M, Vante I, Uppal P, Demory Beckler M, Kesselman MM (2019) Uveitis Sarcoidosis Presumably Initiated After Administration of Shingrix Vaccine. Cureus. 11(6):3278\u201388","journal-title":"Cureus."},{"issue":"8","key":"508_CR33","first-page":"3278","volume":"35","author":"RG Tilton","year":"1994","unstructured":"Tilton RG, Chang K, Corbett JA, Misko TP, Currie MG, Bora NS, Kaplan HJ, Williamson JR (1994) Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci. 35(8):3278\u201388","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"508_CR34","doi-asserted-by":"crossref","unstructured":"M\u00fcller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M (2010) IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 10(4):251-61.","DOI":"10.1016\/S1473-3099(10)70026-8"},{"key":"508_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/971417","volume":"2014","author":"B Urban","year":"2014","unstructured":"Urban B, Bakunowicz-\u0141azarczyk A, Michalczuk M (2014) Immune recovery uveitis: pathogenesis, clinical symptoms, and treatment. Mediators Inflamm. 2014:1\u201310","journal-title":"Mediators Inflamm."},{"issue":"8","key":"508_CR36","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s00417-024-06415-y","volume":"262","author":"N Rodrigues Alves","year":"2024","unstructured":"Rodrigues Alves N, Bar\u00e3o C, Mota C, Costa L, Proen\u00e7a RP (2024) Immune recovery uveitis: a focus review. Graefes Arch Clin Exp Ophthalmol. 262(8):2703\u201312","journal-title":"Graefes Arch Clin Exp Ophthalmol."}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00508-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:07:11Z","timestamp":1781604431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-025-00508-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00508-3","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from the patient, who provided approval for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}